Artiva Biotherapeutics Inc ARTV

$4.28 +0.01 (0.23%)

Valuation

Market cap
300,673,000
Revenue TTM
$0
Net income TTM
$-83,870,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
2,883,900
Avg volume
594,620
Day's range
$4.22 – $4.39
Shares out
48,890,000
Stochastic %K
10%
Beta
2.40
Analysts
Strong Sell
Price target
$35.80

Price

Company profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis,...

Show more

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 267 4467
Website
https://www.artivabio.com
Address
5505 Morehouse Drive, Suite 100, San Diego, United States

Latest news

Stocktwits

toniotoro Oct 28, 6:29 PM
$ABUS as long as no one dies post phase 2 we should be good $ARTV
0 replies
DataClown Oct 28, 5:01 AM
$ARTV SEC 8-K filed 10/27: On 10/22, the board approved the full termination of its lead pipeline AlloNK. Reasons: long-term follow-up failed to confirm durable efficacy, plus a recent Grade 5 fatal adverse event. Roughly 94% of staff to be laid off, and the company is exploring strategic alternatives including sale or liquidation. It raised ~$300M back in May and was still advancing the RA Phase 3 program plus RMAT designation in August. Just ten weeks from a “transformative quarter” to liquidation. Both Needham and Wedbush cut their ratings to Hold on the day. Contrarian-bullish on the stub!!!
0 replies
Bbboston Oct 28, 1:46 AM
$ARTV Terrible news for the patients, and their families. Hopefully it’s something that can be sorted out and not a read block for the technology/approach.
0 replies
None_ Oct 27, 10:18 PM
$ARTV $CRSP $FATE $IPSC $NKTX Artiva's first fatal event being attributed to fludarabine is particularly relevant to the autoimmune CAR field. These are patients with autoimmune disease, not cancer. If you can get away from intensive lymphodepletion, that's a major advantage. Fate's fludarabine-free, less-intensive conditioning potentially removes one of the major sources of risk. It makes the conditioning-free FT819 cohort particularly important. https://www.fiercebiotech.com/biotech/artiva-lays-94-staff-after-deaths-and-durability-sink-autoimmune-cell-therapy
0 replies
Merlintrader Oct 27, 6:51 PM
Biotech recap for Oct 26–27: $ARTV, $BEAM, $MRK and $PFE lead more than 100 news items from these two days, covering trial readouts, FDA decisions, deals, offerings, earnings dates and upcoming conferences. https://www.merlintrader.com/biotech-radar-october-26-27-2026/ Not investment advice.
0 replies
Merlintrader Oct 27, 3:08 PM
$ARTV — Artiva is discontinuing AlloNK development after two Grade 5 events, cutting headcount by about 94% and evaluating strategic alternatives. Preliminary cash: $319.1M. Information only — not investment advice. https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/
0 replies
PennySearch Oct 27, 2:38 PM
⏱️ One-Hour Volume Alert Update $IPST near $2.75 • 1988.97x RVOL Day Range: $2.22 - $3.28 $SXTP near $0.66 • 317.68x RVOL Day Range: $0.59 - $1.20 $ARTV near $4.17 • 58.95x RVOL Day Range: $4.00 - $4.45 Unusual volume does not guarantee direction—it highlights attention. Not financial advice.
0 replies
StocktwitsNews Oct 27, 2:08 PM
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months $ARTV $XBI https://stocktwits.com/news/equity/markets/artiva-scraps-development-of-lead-drug-candidate-after-patient-deaths/cZUe90FRBCW
0 replies